• CONTACT
• NEWS & EVENTS
• RESEARCH & PUBLICATIONS
• NETWORK
• BUSINESS
• COMPANY

1989 -1993 Dr. Iris is Group Leader at the CEPH in Paris

• The CEPH is a Research Institute founded and lead by Nobel laureate Prof. Jean Dausset
• Develops methods for high-throughput (HT) sequencing & data integration
• Realizes that the links between genome & biological processes are non-linear
   
  
• One gene = several proteins = multiple interactions = many context-dependent functions

1993 -1996 Dr. Iris creates & leads Millennium Pharmaceuticals' (USA) HT Sequencing Unit

• He undertakes the first attempts to carry-out physiological modeling via large scale data integration.
• He invents & develops the basic tools and methods required for Integrative Biology.
• Successful completion of two models, leading to the discovery of the UCP2 and EST1 genes and their roles in obesity and hyperglycemia.
• He realizes that since published information is:
• incomplete (to an unknown extent),
• slanted (to an unknown extent),and often
• incorrect (to an unknown extent),
   
• Methodologies to access/generate complementary unbiased information are required

1996-2001 - Dr. Iris is co-founder and C.S.O. of ValiGen SA in Paris

• He invents, develops and patents 4 new differential gene-expression and genotyping technologies.
• He invents and develops the computerized data gathering, data mining, clustering and integration tools & technologies necessary for the industrial development of  Integrative Biology / Systems Biology (European “Eureka” grant: 18.6 M Euros)
• He finalizes the Bio-Graph™ analytical platform based on the " positive selection" concept
• He develops the Tamoxifen Resistance model with Bio-Graph™
• He identifies the limitations of this analytical platform

1999-2001 - Dr. Iris meets Mr. M.Gea and Prof. G.Dine

• Dr. Iris meets M.Gea and Prof. G.Dine, founding members of Centrale-Santé
• Dr. François Iris becomes a member of Centrale-Santé’s Directorate, the Healthcare& Biotech Think Tank of the Centrale's alumni's Association 
• He decides to abandon the Bio-Graph™  platform and  starts working on a second Generation analytical platform (CADI™) based on the " negative selection" concept
• He starts to work on the first version of the Creutzfeldt-Jakob Disease model 

2002-2003 -  Dr. Iris, M. Gea and Dr. Dine initiate the BMSystems project

• Conception of the first European private biotech company specialized in Predictive Integrative biology / Systems Biology 
• Paul-Henri Lampe, and Pablo Santamaria, members of Centrale-Santé Think Tank , decide to join the project
• Development of the CADI™ analytical platform
• Four new models completed (FGF4-driven fibroblast differentiation, hypercholesterolemia,Chronic Fatigue Syndrome, Creutzfeldt Jakob disease) two of which are undergoing independent biological evaluation

2004 - The company is created and starts business operations